Recently, the China Biotechnology Development Center has finalized the list of projects for the 2017 National Key R&D Program “Biomedical Materials R&D and Tissue Organ Repair Replacement†after review and publicity.
The five key special projects are related to the medical field, including the field of “Hangzhou Jienuofei Biotechnology Co., Ltd.†– biomedical materials research and development and tissue organ replacement.
According to the statistics of China Biotechnology Development Center, a total of 782 valid applications were received in five key special projects. After pre-assessment and video defense review, it was finally decided that 167 projects will be funded by the key special projects of the national key R&D plan. The total amount of funds allocated by the state is 249,797. Ten thousand yuan.
Among them, the high-profile “Biomedical Materials R&D and Organ Organ Repair and Replacement†key projects have been established 18 projects, and the total amount of funds allocated by the state totaled 250.31 million yuan. “Jenuofei†was the only bio 3D printing technology company selected. Funded 14.28 million yuan. This is the first time that the enterprises in the Hangzhou Economic Development Zone are the lead units of the project and undertake the national key R&D plan.
The national key R&D plan is a combination of the original National Key Basic Research and Development Program (973 Program), the National High Technology Research and Development Program (863 Program), and the National Science and Technology Support Program. It is a major social welfare research that concerns the national economy and the people's livelihood. And strategic, basic, forward-looking major scientific issues, major common key technologies and products that are related to the core competitiveness of the industry, the overall independent innovation capability and national security, and provide continuous support and guidance for the main areas of national economic and social development. .
At the end of 2016, the national key R&D plan launched the first special project of “Bio-Digital 3D Printing Technology for Personalized Planting and Interventional Devices†for live cell 3D printing during the “13th Five-Year Plan†period. Jienuofei united with Southern Medical University, South China University of Technology, Beijing 301 Hospital, and Shanghai Changzheng Hospital affiliated to the Second Army. Under the guidance of many academicians such as Zhong Shizhen, after a series of links such as pre-assessment and video review, the final The major special grant was obtained in the first place in the total score.
Hangzhou Jienuofei Biotechnology Co., Ltd. has been developing in the development zone for more than 2 years. The company was founded by a number of university professors, Dr. Haigui and the marketing director of the world's top 500 pharmaceutical companies. It is a national high-tech enterprise specializing in providing comprehensive solutions for 3D printing technology in biomedical fields. The company is one of the most complete integrated technology systems in the bio-3D printing industry in the world. It has a complete and independent technical system from bio-3D printing equipment, bio-materials, medical equipment products and services, and is in the leading position in the domestic sub-sector.
The chief scientist of the project, Professor Xu Mingen, the founder of Jienuofei, is the director of Zhejiang University of Electronic Science and Technology-Zhejiang Key Laboratory of Medical Information and Biology 3D Printing. He believes that new technologies and products in the biomedical field will open a big market. Bio 3D printing technology can provide a new technology platform for the biomedical field, bringing great changes in many fields. After more than ten years of hard work, the team has built a complete technology industry system. Bio-3D printing equipment has occupied nearly 50% of the domestic market. Organized products such as bio-3D printing liver unit have been used by large international pharmaceutical companies such as Merck. "The 3D printed tissue and pathological model of human cells can accurately reflect the pharmacological activities of chemical and biological drugs in the human body, thereby improving the success rate of drug screening." He said that the new drug development market derived from technology will be A blue sea.
Although it is still a long time to print a complete liver and kidney that can be used for organ transplantation with 3D technology, the results of "Jenofei" in 3D printing organization can serve a huge commercial market, and drug screening is one of them.
Jienuofei also set its sights on the service provision of the pre-synthesis simulation with higher threshold. For example, left atrial appendage occlusion is a cardiac procedure that greatly tests the clinical ability of a doctor because the location and size of the left atrial appendage are different for each patient. In response to this demand, Boston Scientific, an international company involved in the field of intervention, has developed a product called the left atrial appendage occluder. In the actual surgical design, Boston Scientific cooperated with "Jinuofei" to reconstruct the left atrial appendage structure with the patient's personalized data, and reconstructed the texture, elasticity, size and structure by 3D printing using the material of the left atrial appendage in the simulated body. In the left atrial appendage model, doctors can test on the model to shorten the operation time, increase the safety of the operation, and reduce the risk of surgery. (Qianjiang Evening News)
Tetanus Vaccine,Hepatitis B Vaccine For Adults,Tetanus Booster,Td Vaccine
FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com